A K - ras mutation called KRAS 1 is a biomarker found in
certain patients with lung cancer.
Vascular endothelial growth factor receptor, also called VEGFR, is a biomarker found in
certain patients with lung cancer.
Epidermal growth factor receptor, also called EGFR, is a biomarker found in
certain patients with lung cancer.
Not exact matches
They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell
lung cancer in
patients with a
certain genetic mutation.
UT Southwestern Medical Center researchers are developing a new predictive tool that could help
patients with breast
cancer and
certain lung cancers decide whether follow - up treatments are likely to help.
Among
patients with advanced non-small cell
lung cancer without a mutation of a
certain gene (EGFR), conventional chemotherapy, compared
with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated
with improvement in survival without progression of the
cancer, but not
with overall survival, according to a study in the April 9 issue of JAMA.
«Chemotherapy may be better for
certain patients with advanced
lung cancer.»
Results of an initial study of tumors from
patients with lung cancer or head and neck
cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of
certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.
The drugs are already approved for treatment of
patients with advanced breast
cancer as well as ovarian, pancreatic and
certain lung cancers.
«Our results suggest that administering p38 inhibitors to
certain patients with advanced stages of colon
cancer or
with established metastases could be counterproductive and may enhance cell acquisition of
lung colonization potential,» says Gomis.